Alkem Launches Pertuza Biosimilar in India for HER2-Positive Breast Cancer
This product launch targets a major disease (breast cancer) with an affordable solution, potentially impacting a large patient population and significantly enhancing Alkem's market presence and reputation in the oncology segment.
The launch of an affordable biosimilar for HER2-positive breast cancer addresses a significant healthcare need by improving accessibility and affordability, which is a positive development for patients and strengthens the company's oncology portfolio.
* Alkem Laboratories Limited announced on 22 September 2025, the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer. * Pertuza is an affordable, indigenously-developed and manufactured biosimilar. In its pivotal phase 3 clinical trial, it demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator. * The company aims to expand access to this critical treatment, as the accessibility of pertuzumab in India has been a significant challenge due to cost barriers. * Dr. Vikas Gupta, Chief Executive Officer, stated that the launch reflects Alkem's commitment to developing effective, accessible, and affordable treatment options for breast cancer, which is the most common cancer among Indian women. * This launch further strengthens Alkem's oncology portfolio, which includes other biosimilars such as cetuximab, denosumab, bevacizumab, and romiplostim.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.